Sacituzumab Govitecan and TRAIL Agonists Show Synergistic Lethality in Preclinical Breast Cancer
Preclinical experiments demonstrate that combining the Trop2-directed antibody-drug conjugate sacituzumab govitecan with TRAIL agonists produces synergistic, caspase-dependent apoptotic cell death ...










